{"slug":"fixed-duration","tag":"fixed-duration","variants":["fixed-duration"],"description":"No description yet","count":2,"kinds":{"person":2},"related":[{"slug":"cll","tag":"cll","shared":2},{"slug":"guidelines","tag":"guidelines","shared":1},{"slug":"venetoclax","tag":"venetoclax","shared":1}],"records":[{"id":"kirsten-fischer","kind":"person","name":"Kirsten Fischer","route":"/people/kirsten-fischer/","tldr":"Led CLL14, which established one year of venetoclax plus obinutuzumab as a fixed-duration, chemotherapy-free CLL treatment."},{"id":"william-wierda","kind":"person","name":"William G. Wierda","route":"/people/william-wierda/","tldr":"Led CAPTIVATE, which established fixed-duration ibrutinib plus venetoclax as a first-line option for CLL."}]}